Literature DB >> 22272445

Lung cancer statistics in Luxembourg from 1981 to 2008.

P G Thill1, P Goswami, G Berchem, B Domon.   

Abstract

Lung cancer is the leading cause of cancer-related death in the world and in Luxembourg. As a part of "The health science initiative focused on personalized medicine", Luxembourg aims to participate by developing diagnostics to improve the detection and treatment of lung cancer. In line with this objective, this study made a review of evolution of lung cancer in Luxembourg from 1981 to 2008 and compared this statistics to the situation in the Nordic countries, Europe in general and the World. Incidence data of the national morphological tumour registry and mortality data of the service of statistics of the national ministry of health is depicted in charts with trend lines, in the framework of a statistical evaluation of relevant parameters. The data indicate that while male lung cancer incidence decreased in Luxembourg, the incidence in women and its mortality have doubled over the 28-year span considered. Notwithstanding this increase, the female lung cancer incidence and mortality remain low compared to the Nordic countries and Europe. Interestingly, the study also potentially suggests that the lung cancer pattern follows the smoking pattern in incidence and mortality.

Entities:  

Mesh:

Year:  2011        PMID: 22272445

Source DB:  PubMed          Journal:  Bull Soc Sci Med Grand Duche Luxemb        ISSN: 0037-9247


  7 in total

1.  MiR-451 suppresses cell proliferation and metastasis in A549 lung cancer cells.

Authors:  Pin Yin; Rui Peng; Huimin Peng; Li Yao; Yan Sun; Li Wen; Tianhui Wu; Ji Zhou; Zheng Zhang
Journal:  Mol Biotechnol       Date:  2015-01       Impact factor: 2.695

2.  Contrast-enhanced ultrasound with a novel nanoparticle contrast agent for clinical diagnosis in patients with non-small cell lung cancer.

Authors:  Na Li; Lu Han; Hui Jing
Journal:  Exp Ther Med       Date:  2017-08-16       Impact factor: 2.447

3.  Ultrasonic diagnosis combined with targeted ultrasound contrast agent improves diagnostic sensitivity of ultrasonic for non-small cell lung cancer patients.

Authors:  Xiaohong Zhang; Can Xiao
Journal:  Exp Ther Med       Date:  2018-05-23       Impact factor: 2.447

4.  Sulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cells.

Authors:  Hsiu-Ni Kung; Tsai-Yun Weng; Yu-Lin Liu; Kuo-Shyan Lu; Yat-Pang Chau
Journal:  PLoS One       Date:  2014-02-05       Impact factor: 3.752

5.  Genetic variation of lncRNA GAS5 contributes to the development of lung cancer.

Authors:  Weihao Li; Kai Huang; Fengbiao Wen; Guanghui Cui; Haizhou Guo; Song Zhao
Journal:  Oncotarget       Date:  2017-08-03

6.  Clinical significance of calcium-binding protein S100A8 and S100A9 expression in non-small cell lung cancer.

Authors:  He Huang; Qingdong Huang; Tingyu Tang; Liang Gu; Jianzong Du; Zhijun Li; Xiaoling Lu; Xiaoxi Zhou
Journal:  Thorac Cancer       Date:  2018-05-07       Impact factor: 3.500

7.  Long noncoding RNA VPS9D1-AS1 augments the malignant phenotype of non-small cell lung cancer by sponging microRNA-532-3p and thereby enhancing HMGA2 expression.

Authors:  Xiao Han; Tianren Huang; Junqing Han
Journal:  Aging (Albany NY)       Date:  2020-01-05       Impact factor: 5.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.